Century Therapeutics posted a GAAP net loss of USD 34.6 million, widening from USD 32.5 million a year earlier.
R&D expense fell 27.1% to USD 19.6 million, due to lower headcount and facility costs tied to portfolio prioritization.
G&A expense dropped 25.6% to USD 5.8 million; cash, cash equivalents, and investments climbed to USD 197.2 million.
Runway extended into 1Q 2029; CNTY-813 IND filing remains on track for 4Q 2026 with initial clinical data expected in 2H 2027.
Pre-IND FDA meeting aligned on nonclinical package, Phase 1 manufacturing and testing, and Phase 1/2 trial design; CNTY-308 still slated for clinic entry in 2026.
CNTX•
